Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 11/20 | 0.40 |
| ▸ | CTSS | P25774 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19326572 | 0.93 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL17080907 | 0.93 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL31240095 | 0.93 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL15156428 | 0.88 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15157513 | 0.88 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13483252 | 0.88 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15295107 | 0.85 | CTSK (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL15083553 | 0.85 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL25658173 | 0.83 | CA1 (0.42) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL16288233 | 0.82 | CYP1A2 (0.36) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | CYP1A2 3302/4885CYP2C9 1806/4885CYP2C19 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.